Updated evidence-based treatment algorithm in pulmonary arterial hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) requires effective risk-benefit assessment for therapeutic options.
• Existing treatments for PAH vary in efficacy and evidence base.

Purpose of the Study:

• To define risk-benefit profiles for various therapeutic options in pulmonary arterial hypertension (PAH).
• To propose an evidence-based treatment algorithm for PAH management.
• To evaluate approved and off-label drugs for PAH based on clinical trial data.

Main Methods:

• Review of uncontrolled and controlled clinical trials for PAH compounds and procedures.
• Application of a grading system for treatment evidence levels derived from controlled trials.
• Development of a treatment algorithm incorporating regulatory-approved and other available drugs.

Main Results:

• Oral anticoagulation recommended for most PAH patients; diuretics and oxygen for specific symptoms.
• High-dose calcium-channel blockers are limited to a small subset of vasoreactive patients.
• Sequential or combination therapies with PDE-5 inhibitors, ERA, or epoprostenol are outlined based on functional class and response.

Conclusions:

• An evidence-based algorithm guides PAH treatment selection, prioritizing approved therapies.
• Combination therapy is recommended for PAH patients not achieving WHO functional class III on monotherapy.
• Surgical interventions like atrial septostomy and lung transplantation are reserved for refractory cases.